| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
phase 1 data readout example | Phase 1 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Artelo Biosciences, Inc.
$0.73
+0.01 (+1.55%)
Market Cap
2.55 M
EPS
-3.86
P/E Ratio
-
Value Trade
374.53 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
773.00 K
Operating CF
-1.19 M
Total Assets
12.52 M
Total Liabilities
5.85 M
Equity
6.67 M
-3.29 %
Week
-31.59 %
1 Month
-70.32 %
3 Month
-83.49 %
6 Month
-99.64 %
5 Year
-99.89 %
All Time
Cash Data
Cash Position
10.27 M
Monthly Burn
397.00 K
Runway
23.2 mo
Burn Trend
SEC Filing
May 14, 2026
Overview
Volume
91.96 K
52 Week Range
0.71 - 31.65
% held by Insiders
2.42 %
% held by Institutions
7.63 %
Enterprise Value
-7.73 M
Total Shares
3.49 M
Short %
4.97 %
Float Shares
2.76 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Artelo Biosciences, Inc.
385Total events
7Upcoming
41Tier-1 (high impact)
2018 – 2038Coverage
Upcoming catalysts 2
TBD
T2First Patient Dosed
Subscribe to view catalyst details
TBD
T2Trial Initiation
Subscribe to view catalyst details
Event history 2
TBD
▲PublicationPresentation
Subscribe to view catalyst details
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-09-30 | ART26.12 | phase 1 data readout | Phase 1 | — | – | – | – |
2026-09-30 | ART26.12 | phase 1 data readout | Phase 1 | — | – | – | – |
2026-09-30 | ART26.12 | phase 1 data readout | Phase 1 | — | – | – | – |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
ART27.13 | cancer-related anorexia cachexia syndrome | Phase 2 | 2026-07-13 | improvements in body weight and lean body mass, increased activity levels, and favorable safety profile at doses up to 1300 µg/day Read More | Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Read More | |
ART27.13 | cancer-related anorexia cachexia syndrome | Phase 2 | 2026-07-13 | improvements in body weight and lean body mass, increased activity levels, and favorable safety profile at doses up to 1300 µg/day Read More | Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Read More | |
ART27.13 | cancer-related anorexia cachexia syndrome | Phase 2 | 2026-07-13 | improvements in body weight and lean body mass, increased activity levels, and favorable safety profile at doses up to 1300 µg/day Read More | Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ARTL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ARTL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ARTL▲ +1.6%today
Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma
Artelo Biosciences has announced the enrollment of the first patient in its Phase 2 clinical trial, the DREAM study, evaluating ART27.13 for glaucoma treatment. This study aims to assess the efficacy of ART27.13, a synthetic cannabinoid, in lowering intraocular pressure. Initial results are anticipated in Q4 2026, with funding provided by Glaucoma UK and the HSC R&D Division.
Read more →ARTLNew Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition
A recent analysis published in the British Journal of Clinical Pharmacology reveals that widely sold non-prescription CBD products lack therapeutic efficacy due to inadequate dosing. Artelo's proprietary formulation, ART12.11, aims to enhance bioavailability and address these limitations. The study underscores the importance of evidence-based drug development in optimizing CBD treatments.
Read more →ARTLArtelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions
Artelo Biosciences announced promising results from a nonclinical study of ART26.12, a FABP5 inhibitor, showing significant pain relief in osteoarthritis comparable to naproxen, but with less gastric damage. The findings suggest ART26.12 could provide a safer alternative for chronic pain management. Clinical trials for ART26.12 are set to begin in Q4 2026.
Read more →ARTL▲ +10.5%on this newsshared move
Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026
Artelo Biosciences has reminded shareholders to vote in advance of its Annual Meeting on July 17, 2026. The company emphasizes the importance of submitting proxies to establish quorum and efficiently conduct business. Shareholders are encouraged to review proxy materials and participate in the voting process.
Read more →ARTLArtelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy
Artelo Biosciences has announced positive results from nonclinical studies of ART27.13, a cannabinoid receptor agonist, in treating neuropathic pain associated with paclitaxel chemotherapy. The findings suggest that ART27.13 may have broader applications in cancer supportive care, particularly for patients suffering from anorexia cachexia syndrome. Interim results from the CAReS Phase 2 clinical study also indicate improvements in body weight and activity levels.
Read more →ARTLArtelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
Artelo Biosciences announced promising preclinical data for ART26.12, a selective FABP5 inhibitor, showing its potential to alleviate neuropathic pain associated with spinal cord injury. The findings, presented at a symposium in France, suggest ART26.12 could serve as a novel, non-opioid analgesic. The company emphasizes the need for effective treatments in chronic pain management.
Read more →ARTLArtelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026
Artelo Biosciences presented findings at the ICRS 2026 Annual Symposium, highlighting the potential of its FABP5 inhibitor, ART26.12, in modulating lipid-signaling pathways across various disease models. The research indicates a mechanistic link involving linoleic acid, suggesting broad therapeutic applications. The company emphasizes the drug's favorable safety profile and its potential in treating conditions like chemotherapy-induced peripheral neuropathy.
Read more →ARTLArtelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026
Artelo Biosciences presented promising Phase 1 clinical data for ART26.12, a selective FABP5 inhibitor, at the ICRS 2026 Annual Symposium. The study showed a favorable safety profile and predictable pharmacokinetics in healthy volunteers. Additionally, new biomarker analyses indicated potential indicators of target engagement, supporting further clinical development of ART26.12.
Read more →ARTLArtelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success
Artelo Biosciences presented promising data on its lead candidate ART26.12 at a conference, highlighting a low-risk metabolite profile from a recent clinical study. The findings suggest that the majority of drug-related exposure comes from the parent compound, indicating a favorable pharmacokinetic profile. This could streamline future development and reduce risks associated with drug metabolism.
Read more →ARTLArtelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results
Artelo Biosciences has released a business update detailing its progress in clinical studies and financial results for the first quarter of 2026. The company noted significant advancements in its lead drug ART26.12, which is advancing to multiple ascending dose studies after promising Phase 1 results. ART27.13 also showed positive interim results for patients with cancer-related anorexia. Artelo has strengthened its financial position through a capital raise, allowing further development of its pipeline and fostering potential strategic partnerships.
Read more →ARTL▼ -5.3%on this news
Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development
Artelo Biosciences has announced a strategic collaboration with ScienceMachine to enhance the development of its FABP5 inhibitor platform. This partnership aims to leverage AI technology to analyze extensive biological datasets, potentially accelerating the identification of new mechanisms and therapeutic opportunities. The collaboration is expected to provide insights into ART26.12, Artelo's lead FABP5 inhibitor, and improve drug development strategies.
Read more →ARTLArtelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile
Artelo Biosciences, Inc. announced the publication of a peer-reviewed article highlighting ART26.12, its FABP5 inhibitor, as a potential first-in-class pain treatment. The article provides evidence that FABP5 inhibition can lead to analgesic effects across various pain models. Notably, the drug showed excellent safety in a Phase 1 study, with no adverse events reported. Artelo plans to advance ART26.12 into a multiple ascending dose study, building on its promising preclinical results.
Read more →ARTL▲ +10.3%on this news
Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements
Artelo Biosciences has announced that it has regained compliance with Nasdaq listing requirements. This follows a confirmation letter from Nasdaq stating that the company met necessary regulations after holding a reconvened annual meeting. The company is now focusing on progressive steps in its development pipeline, specifically on its investigational drugs ART27.13 and ART26.12. CEO Gregory D. Gorgas expressed confidence in the company’s ability to create long-term value for shareholders.
Read more →ARTL▼ -17.2%on this news· ran to -33% by day 3
Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Artelo Biosciences announced a private placement of approximately $11 million, involving the sale of shares and warrants. The placement, priced at $3.45 per share, is expected to close around March 30, 2026. Proceeds will be used for working capital and debt repayment, although the company cannot guarantee the exercise of the warrants.
Read more →ARTL▼ -17.2%on this news· ran to -33% by day 3shared move
Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Artelo Biosciences, Inc. announced the successful closing of its private placement, raising approximately $11.0 million through the issuance of shares and warrants. The private placement was facilitated by H.C. Wainwright & Co. The company plans to use the proceeds for working capital, general corporate purposes, and the repayment of bridge debt. Additionally, there is potential for up to $20.4 million in gross proceeds from warrant exercises, though such exercises are not guaranteed.
Read more →ARTL▼ -16.2%on this news· ran to +51% by day 3shared move
Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength
Artelo Biosciences is expanding into the $16.3 billion glaucoma market with a fully funded clinical study, highlighting its multi-platform pipeline. The company is advancing three distinct clinical-stage programs in oncology support, neuropathic pain, and CNS disorders, while also receiving positive interim Phase 2 data for its lead compound, ART27.13. Artelo's strategic partnerships and strong patent protection further enhance its market position.
Read more →ARTL▼ -16.2%on this news· ran to +51% by day 3shared move
Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments
Artelo Biosciences has announced the expansion of its ART27.13 development, aiming to explore its potential as a companion therapy for GLP-1 treatments to preserve muscle mass. The initiative is backed by recent positive findings from preclinical studies and the initiation of non-clinical studies. Additionally, Artelo has filed a provisional patent to protect this innovative use of cannabinoid receptor agonism. This development aligns with the rising demand for GLP-1 treatments, highlighting an unmet need for mitigating muscle loss associated with these therapies.
Read more →ARTL▲ +50.7%on this news
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients
Artelo Biosciences has entered into a clinical study agreement with the Belfast Health and Social Care Trust to investigate the effects of its synthetic cannabinoid, ART27.13, in glaucoma patients. Funded by Glaucoma UK and the HSC R&D Division, this study is set to explore ART27.13's ability to lower intraocular pressure, which is critical for managing glaucoma. The first patient enrollment is expected in the second quarter of 2026. This initiative represents a potential expansion of ART27.13's therapeutic uses beyond its original indications.
Read more →ARTL▲ +16.9%on this news· ran to +92% by day 3shared move
ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 206) F-2 Consolidated Balance Sheets at
Artelo Biosciences, Inc. has released its audited financial statements for the fiscal years ending December 31, 2025, and 2024. The report reveals that the company has incurred increasing losses, with a net loss of $12,879 in 2025 compared to $9,826 in 2024. Concerns have been raised regarding the company's ability to continue as a going concern due to a significant capital deficiency and liabilities outpacing assets. The auditors found no critical audit matters but noted the ongoing operational challenges facing the company.
Read more →ARTLArtelo Biosciences Announces Reverse Stock Split
Artelo Biosciences announced a 3-for-1 reverse stock split, effective March 10, 2026. This decision, made by the Board of Directors, aims to enhance the marketability and liquidity of the company's common stock. Following the split, shareholders will see their shares consolidated, with no impact on their percentage ownership. The company plans to maintain transparency by inviting shareholders to review further details in an 8-K filing.
Read more →ARTLArtelo Biosciences Announces Reverse Stock Split Shares Expected to Begin Trading on a Split-Adjusted Basis on
Artelo Biosciences, Inc. announced a 3-for-1 reverse stock split, approved by its Board on February 27, 2026. The shares are expected to begin trading on a split-adjusted basis on March 10, 2026. The reverse split aims to increase the price per share to boost marketability and liquidity, while shareholders' ownership percentages will remain the same. The company's current warrants and other derivatives will automatically adjust to reflect this split.
Read more →ARTLArtelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results
Artelo Biosciences reported significant clinical progress in its pipeline during the fiscal year 2025. The company successfully completed a Phase 1 study for ART26.12, showing a favorable safety profile, and announced positive interim results for ART27.13 in cancer patients. Additionally, Artelo received favorable regulatory guidance for ART12.11, paving the way for future studies.
Read more →ARTLArtelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
Artelo Biosciences has commended the recent Presidential Executive Order aimed at enhancing CBD research and accessibility, viewing it as a validation of CBD's medicinal potential. The company highlights its proprietary compound ART12.11, which combines cannabidiol with tetramethylpyrazine, showing improved pharmacokinetics and efficacy in preclinical models. This initiative, according to Artelo, underscores the urgent need for rigorously controlled clinical studies to ensure the safety and efficacy of cannabinoid treatments. The Executive Order aligns closely with Artelo's goals to facilitate better access to standardized CBD therapies for patients.
Read more →ARTL▼ -8.3%on this news
Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
Artelo Biosciences has published a new peer-reviewed study showcasing that its FABP5 inhibitor, SBFI103, significantly reduces anxiety and depression behaviors in chronic stress models. The research highlights the drug's effects on hippocampal neurogenesis and key components of the endocannabinoid system. These findings bolster the scientific rationale for developing SBFI103 further, with plans for human studies underway. The study was conducted by Dr. Steven Laviolette's laboratory and partially funded by Artelo.
Read more →ARTL▼ -8.2%on this news
Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
Artelo Biosciences announced its Q3 2025 financial results and provided a business update. The company highlighted positive interim Phase 2 data for ART27.13, which has attracted significant partnering interest. Additionally, ART26.12 is moving towards a multiple ascending dose study, indicating promising developments in their clinical pipeline. The company aims to address significant unmet needs in various medical conditions.
Read more →ARTL▼ -38%on this news
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
Artelo Biosciences has published a peer-reviewed article on the role of Fatty Acid Binding Protein 3 (FABP3) in cancer, highlighting its significance in tumor progression. The article is part of a trilogy exploring the roles of various FABP isoforms in cancer biology. The findings suggest that inhibiting FABP3 may offer therapeutic benefits in treating cancer, reinforcing Artelo's commitment to advancing innovative cancer therapies.
Read more →ARTLArtelo Biosciences Names Veteran Life Sciences Executive Mark Spring, CPA, as Chief Financial Officer
Artelo Biosciences has appointed Mark Spring as Chief Financial Officer, effective November 1, 2025. With 30 years of experience in life sciences, Spring has previously served in various financial leadership roles. His expertise is expected to enhance Artelo's financial operations and support its clinical pipeline and corporate growth initiatives.
Read more →ARTLArtelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
Artelo Biosciences announced expanded clinical data for ART26.12 and ART27.13 at the Cannabinoid & Endocannabinoid Drug Development Summit. ART26.12's Phase 1 data indicated safety and predictable dosing, while ART27.13's interim Phase 2 data showed significant weight gain in cancer patients. Both drugs aim to address critical issues in cancer-related anorexia and pain management.
Read more →ARTLArtelo Biosciences Announces Closing of $2.0 Million Public Offering
Artelo Biosciences has announced the successful closing of a $2.0 million public offering, which included 441,210 shares of common stock and pre-funded warrants. The offering was managed by R.F. Lafferty & Co., Inc. and was conducted under a previously filed shelf registration statement. The funds raised will support the company's pipeline focused on various medical conditions.
Read more →ARTL▼ -21.5%on this newsshared move
Artelo Biosciences Announces Pricing of $2.0 Million Public Offering
Artelo Biosciences announced a public offering of 441,210 shares at $4.40 each, aiming to raise approximately $2.0 million. The offering includes pre-funded warrants and is expected to close on October 1, 2025. The company has granted underwriters a 45-day option to purchase additional shares. The offering is conducted under an effective registration statement with the SEC.
Read more →ARTL▼ -21.5%on this newsshared move
Artelo Biosciences Announces Proposed Underwritten Public Offering
Artelo Biosciences has announced a proposed underwritten public offering of its common stock and/or pre-funded warrants. The offering is subject to market conditions and is being managed by R.F. Lafferty & Co., Inc. The company aims to raise capital to support its clinical-stage pharmaceutical projects focused on various medical conditions. A prospectus supplement will be filed with the SEC detailing the offering terms.
Read more →ARTL▲ +6.2%on this news· ran to -17% by day 1shared move
Artelo Biosciences Announces Presentation of Positive Interim Phase 2 CAReS Data on ART27.13 at the 2025 Cancer Cachexia Society Conference
Artelo Biosciences presented positive interim data from its Phase 2 CAReS study on ART27.13 at the Cancer Cachexia Society Conference. The data indicated significant improvements in weight, lean body mass, and daily activity among patients with cancer anorexia-cachexia syndrome. The findings suggest ART27.13 could enhance the quality of life for affected patients.
Read more →ARTLArtelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
Artelo Biosciences has published preclinical data demonstrating that its proprietary cocrystal ART12.11 significantly reduces stress-induced depression and anxiety symptoms more effectively than cannabidiol alone. The study, conducted with Western Ontario University, highlights ART12.11's superior oral bioavailability and its potential as a novel treatment for mood disorders. The MHRA has also provided guidance to streamline the clinical trial process for ART12.11.
Read more →ARTLArtelo Biosciences Announces Closing of $3.0 Million Public Offering
Artelo Biosciences has successfully closed a $3.0 million public offering consisting of 640,924 shares of common stock priced at $4.40 each, along with pre-funded warrants for additional shares. The offering's gross proceeds will support the company's developmental initiatives in various therapeutic areas, including cancer and pain management. Underwriters have the option to purchase additional shares, reflecting a strategy to raise further capital. This move follows the effective registration of their offering with the SEC, enhancing the company's operational finance capabilities.
Read more →ARTL▼ -50.3%on this newsshared move
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
Artelo Biosciences has priced its underwritten public offering of 640,924 shares at $4.40 each, alongside pre-funded warrants to purchase additional shares. The total gross proceeds from this offering are expected to be approximately $3.0 million, before costs. Investor interest will be gauged following the offering's closing on September 5, 2025, subject to regulatory conditions. The company aims to use the funds for the development of therapies targeting conditions like cancer and pain.
Read more →ARTLArtelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
Artelo Biosciences announced positive interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer anorexia-cachexia syndrome (CACS). The study revealed a mean weight gain of 6.4% after 12 weeks, contrasting sharply with a mean weight loss of 5.4% in the placebo group. ART27.13 was well tolerated with no serious adverse effects reported. These promising data underline the potential of ART27.13 to address significant unmet needs in cancer patient care.
Read more →ARTLArtelo Biosciences Affirms Strong Partnering Outlook for ART27.13 Following Positive Interim Phase 2 CAReS Results
Artelo Biosciences has announced positive interim results from its Phase 2 CAReS trial for ART27.13, aimed at treating cancer anorexia-cachexia syndrome. The results indicate significant improvements in weight and lean body mass among patients, prompting strong interest from multiple pharmaceutical partners. Due to these developments, the company believes it can secure a licensing deal rather than fund a Phase 3 trial internally. ART27.13 represents a promising therapy in a market that currently lacks approved treatments for this condition.
Read more →ARTLArtelo Biosciences Announces New Data from an Initial Food Effect Investigation with ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences announced positive results from a food effect study of ART26.12, a novel non-opioid treatment for pain. The preliminary data indicated a favorable safety profile, with no serious adverse events reported among participants. Consistent pharmacokinetics were observed whether the drug was administered with food or in a fasted state. With these encouraging findings, Artelo prepares to advance to a multiple ascending dose trial later this year to assess ongoing safety and tolerability.
Read more →ARTLArtelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
Artelo Biosciences (ARTL) has announced a business update alongside its financial results for the second quarter of 2025. The company reported positive results from its Phase 1 safety study of ART26.12, which is set to advance to a multiple ascending dose study later this year. Moreover, ART27.13 is on track for a Phase 2 data readout in the third quarter of 2025, targeting cancer anorexia-cachexia syndrome. Additionally, the preclinical candidate ART12.11 shows promise for treating depressive-like behaviors, with a human trial expected in 2026. Despite a net loss increase, the company maintains a focus on addressing significant unmet medical needs through innovative therapies.
Read more →ARTL▲ +20.1%on this newsshared move
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13
Artelo Biosciences has announced a Notice of Allowance from the European Patent Office for its patent application regarding the formulation of ART27.13, a cannabinoid agonist in Phase 2 evaluation for cancer-related anorexia. This patent extends protection through December 2041 and is seen as a significant step in the company’s intellectual property strategy. The drug aims to offer a potential treatment for the severe appetite loss experienced by over 60% of advanced cancer patients, with initial clinical trial results indicating favorable safety and efficacy findings. The company expects to release initial Phase 2 study results in the third quarter of 2025.
Read more →ARTLArtelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset
Artelo Biosciences has announced a $9.475 million at-the-market private placement to initiate its Solana treasury strategy, making it the first publicly traded pharmaceutical company to adopt Solana's native cryptocurrency, SOL, as a core reserve asset. The funds raised will support the treasury initiative and the ongoing development of Artelo's proprietary therapeutics. Lead investor Bartosz Lipiński, a former head of engineering at Solana Labs, will act as a technical partner to guide the company's entry into the digital asset space. The initiative reflects Artelo's commitment to innovative capital management and aims to enhance long-term value for shareholders.
Read more →ARTL▼ -14%on this news· ran to -24% by day 3shared move
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company’s Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
Artelo Biosciences has received positive guidance from the UK's MHRA for its ART12.11 Phase 1 trial, a cocrystal combining CBD and TMP aimed at treating anxiety and depression. The guidance allows for a streamlined clinical trial application, setting clear pathways for the initiation of human studies. ART12.11 shows promising efficacy in preclinical models compared to existing treatments, with the potential for accelerated access under the Innovative Licensing and Access Pathway. The company plans to enter the clinic with ART12.11 early next year, bolstered by the reassuring regulatory support.
Read more →ARTL▼ -16.2%on this news· ran to -47% by day 3
ARTELO BIOSCIENCES, INC. INDEX TO AUDITED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 206). 2 Consolidated Balance Sheets at
Artelo Biosciences, Inc. has published its audited financial statements for the years ending December 31, 2024, and 2023. The financial results indicate recurring losses and a substantial decline in total assets, which have raised concerns about the company's ability to sustain its operations. The report also highlights a net capital deficiency and the related doubt regarding the company's continued viability. The auditors found no critical audit matters but noted the financial statements are presented fairly in accordance with U.S. accounting principles.
Read more →ARTL▲ +35.8%on this news· ran to +79% by day 1shared move
Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences has announced positive preclinical efficacy data for its lead drug candidate, ART26.12, at the 35th Annual ICRS Symposium. In models of osteoarthritis pain, ART26.12 showed significant pain relief and increased plasma levels of beneficial endocannabinoids. The results indicate that it might be a safer alternative to NSAIDs, with sustained efficacy over extended treatment without tolerance development. The study's promising findings enhance ART26.12's potential for further clinical development in chronic pain management.
Read more →ARTL▲ +42.5%on this news· ran to +184% by day 3shared move
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
Artelo Biosciences announced positive preclinical data for its cocrystal drug candidate, ART12.11, at the 35th Annual International Cannabinoid Research Society Symposium. The data show that ART12.11 exhibits robust antidepressant-like effects and improves cognitive function in a stress-induced depression model in animals. It reversed behavioral impairments comparable to the established SSRI sertraline while offering unique cognitive benefits. This positions ART12.11 as a potential next-generation treatment in the antidepressant market.
Read more →ARTL▲ +95.4%on this news
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
Artelo Biosciences announced positive results from its first-in-human study of ART26.12, a novel non-opioid treatment candidate for persistent pain. The study showed excellent safety and tolerability, with no drug-related adverse events noted. Furthermore, ART26.12's pharmacokinetic profiles supported its favorable safety margins, indicating potential for maximum efficacy in future studies. The company is progressing with further clinical evaluations, aiming to fill a significant gap in non-opioid pain management solutions.
Read more →ARTL▲ +12.1%on this news· ran to +55% by day 3shared move
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
Artelo Biosciences has secured approximately $1.425 million through an At-the-Market private placement financing. The company will issue common stock and pre-funded warrants while using a portion of the proceeds to announce clinical results for its drug candidates ART26.12 and ART27.13. Additionally, Artelo plans to allocate funds towards purchasing digital currency and addressing general corporate expenses. The transaction is subject to customary closing conditions and will not allow immediate resale of the securities involved.
Read more →ARTLArtelo’s Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
Artelo Biosciences presented positive findings on ART26.12, a Fatty Acid Binding Protein 5 inhibitor, at the British Pain Conference. The drug demonstrated comparable analgesic effects to naproxen in animal studies and is currently in human trials aimed at treating osteoarthritis pain. With promising outcomes in weight-bearing capability of OA-affected rats, ART26.12 could offer a novel, non-opioid alternative for pain management. results from the first Phase 1 trial are expected in the second quarter of 2025.
Read more →ARTLArtelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results
Artelo Biosciences announced its business update and financial results for the first quarter of 2025, reporting a net loss of $2.4 million. The company highlighted key clinical advancements, including the completion of Phase I enrollment for ART26.12 and promising peer-reviewed data for its drug ART12.11. Future milestones are anticipated within the next year for several ongoing studies, including the Phase 2 CAReS study for ART27.13. However, the company also faces financial challenges with limited cash reserves and reliance on upcoming funding.
Read more →ARTLArtelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12’s Effectiveness in Treating Psoriasis
Artelo Biosciences has announced the publication of new research in the Journal of Investigative Dermatology, demonstrating the effectiveness of ART26.12 for treating psoriasis. The study indicates that ART26.12, a small-molecule inhibitor of Fatty Acid Binding Protein 5, exhibits positive effects in both in vitro and in vivo models, comparable to existing treatments that carry significant side effects. Early results suggest that it may offer a safer alternative for patients. Enrollment in a Phase 1 study of ART26.12 has been completed, with data expected in the near future.
Read more →ARTL▼ -6.9%on this news
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
Artelo Biosciences, a clinical-stage pharmaceutical company, will present insights on its lead FABP5 inhibitor, ART26.12, at the 4th ACE Drug Discovery Summit on April 3, 2025. The presentation by Myles Osborn will focus on data examining the inhibition of FABP5 across multiple disease models, highlighting its potential therapeutic applications. ART26.12 is expected to enter its Phase 1 trial data release in Q2 2025, which may provide critical information for treating chemotherapy-induced peripheral neuropathy and other conditions. The company aims to develop innovative therapies that modulate lipid-signaling pathways.
Read more →ARTL▼ -6.5%on this news
Artelo Biosciences Provides Business Update and Reports Fiscal 2024 Year-End Financial Results
Artelo Biosciences announced its fiscal 2024 financial results and provided a business update on March 3, 2025. The company is making significant progress in its clinical programs, with key milestones expected in 2025, including the completion of Phase I trials for ART26.12 and initial data from ART27.13's Phase 2 CAReS trial. Despite a slight increase in net loss to $9.8 million for the year, Artelo's cash position remains at $2.3 million as of December 31, 2024. The developments in their drug candidates highlight Artelo's commitment to addressing unmet medical needs in various therapeutic areas.
Read more →ARTL▼ -14.4%on this news
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex
Artelo Biosciences announced promising nonclinical results for ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine, demonstrating pharmacokinetic efficacy comparable to Epidiolex. The findings were presented at the International Medical Cannabis Conference in Switzerland, highlighting that solid tablet forms may enhance stability and patient compliance. The proprietary formulation is anticipated to address the limitations of current CBD products, with advancements in bioavailability and efficacy. Artelo aims to further develop ART12.11 for use in human clinical trials.
Read more →ARTLArtelo Biosciences to Present its New Data on ART12.11 Tablets Compared to Epidiolex at the IMCCB-25 Conference in Bern, Switzerland
Artelo Biosciences is set to present new data on its proprietary ART12.11 tablets at the IMCCB-25 conference in Bern, Switzerland, on February 14, 2025. The data will show comparable pharmacokinetics between ART12.11 and Epidiolex based on canine studies. ART12.11, a cocrystal formulation of cannabidiol and tetramethylpyrazine, has been found to exhibit superior pharmacokinetic properties. The presentation aims to highlight the potential advantages and advancements of this novel formulation in the cannabis-based therapeutic space.
Read more →ARTLArtelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12
Artelo Biosciences announced the successful completion of a safety review for the first cohort in its Phase 1 study of ART26.12, a selective Fatty Acid Binding Protein 5 inhibitor. The study aims to assess the safety and pharmacokinetics of ART26.12, with results expected in the first half of 2025. This trial is a significant milestone in developing novel treatments for conditions like chemotherapy-induced peripheral neuropathy, where no FDA-approved therapies currently exist. Artelo's innovative approach positions it as a key player in addressing unmet needs in pain management and related indications.
Read more →ARTL▼ -5.4%on this news
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
Artelo Biosciences announced the presentation of Phase 1 clinical data for ART27.13, a treatment for cancer-related anorexia, at a recent international conference. The drug was well tolerated in the study, showing significant effects on weight stabilization or gain for two-thirds of participants over one month. Currently, the study is moving to Phase 2, with enrollment ongoing across multiple sites in various countries. The company aims to address a significant unmet need, as there are no approved therapies for this condition in the UK, US, or Europe.
Read more →ARTL▲ +17.3%on this news
Artelo Biosciences to Present Key Data on Three Development Programs at the 7th Cannabinoid Drug Development Summit
Artelo Biosciences, Inc. announced key presentations at the 7th Cannabinoid-Derived Drug Development Summit. Professor Saoirse O'Sullivan will showcase data on three of the company's experimental therapies: ART26.12, ART27.13, and ART12.11. These programs aim to address serious medical conditions, including cancer cachexia and neuropathic pain, and feature innovations like a selective FABP5 inhibitor and a novel cannabidiol cocrystal. The presentations are expected to explore potential collaborations and advancements in cannabinoid-related research.
Read more →ARTL▼ -6%on this newsshared move
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium
Artelo Biosciences has presented promising new data for ART26.12, a novel FABP5 inhibitor, which shows effectiveness in alleviating osteoarthritis pain, outperforming naproxen in a rodent model. This development was shared at the 13th Annual Musculoskeletal Repair and Regeneration Symposium. With FDA clearance for first-in-human clinical trials expected to commence soon, the findings add to the growing body of evidence supporting ART26.12's potential as a non-opioid treatment option. The research underscores an encouraging step towards addressing severe pain management challenges in osteoarthritis.
Read more →ARTL▼ -5.4%on this news· ran to -16% by day 3shared move
Artelo Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences reported its financial results for Q3 2024, showing a reduced net loss compared to the previous year as they advance their clinical pipeline. The company has received FDA clearance to initiate trials for ART26.12 targeting chemotherapy-induced peripheral neuropathy and is on track with its Phase 2 CAReS trial for ART27.13, which aims to treat cancer-related anorexia. They also plan to start trials for ART12.11, a new cocrystal treatment for anxiety and depression in 2025.
Read more →ARTL▲ +9.7%on this news
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program
Artelo Biosciences has announced that its lead clinical FABP inhibitor, ART26.12, has been accepted into the NIH's Preclinical Screening Platform for Pain under the HEAL Initiative. This program evaluates non-opioid treatments for pain management and aims to address the overdose epidemic. Following FDA clearance for a first-in-human study, initial results for ART26.12 are anticipated in the first half of 2025. The acceptance into the platform is viewed as an advancement for the development of ART26.12.
Read more →ARTLArtelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th
Artelo Biosciences, Inc. (Nasdaq: ARTL) has announced its participation in the Maxim Group 2024 Virtual Healthcare Summit scheduled for October 15-17, 2024. CEO Gregory D. Gorgas will host a fireside chat on October 16 at 4:00 p.m. ET with Maxim's Senior MD, Jason McCarthy. The event aims to provide insights into the company's clinical-stage therapeutic developments focused on various medical conditions, including cancer and pain management.
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Artelo Biosciences, Inc. announced that CEO Gregory D. Gorgas will participate in the H.C. Wainwright 26th Annual Global Investment Conference scheduled for September 9-11, 2024. The presentation will be available on-demand for registered attendees and can also be accessed via the company's website. Additionally, the management team will hold one-on-one meetings with qualified investors during the conference, highlighting the company's commitment to investor engagement.
Read more →ARTLArtelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences reported its financial results for Q2 2024, highlighting key advancements in its clinical pipeline. The company received FDA approval to start trials for ART26.12 and anticipates significant clinical readouts in the next 18 months. With a solid cash position and successful preclinical study presentations, Artelo aims to address critical medical needs in cancer-related conditions. Despite an increase in net loss, the company maintained optimism about its growth potential.
Read more →ARTLArtelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor
Artelo Biosciences has received FDA clearance for its Investigational New Drug application for ART26.12, a selective inhibitor aimed at treating chemotherapy-induced peripheral neuropathy (CIPN). This marks a significant step forward as there are currently no FDA-approved treatments for CIPN, which often leads to dose reductions in cancer therapy. ART26.12 is expected to enter its first Phase 1 clinical trial, with results anticipated in the first half of 2025. The compound is part of Artelo's proprietary Fatty Acid Binding Protein platform, which has shown promise in addressing multiple conditions related to pain and nerve damage.
Read more →ARTLArtelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences revealed promising data on ART12.11, a cocrystal drug candidate combining cannabidiol and tetramethylpyrazine, at the 34th Annual International Cannabinoid Research Society Symposium. The studies presented highlighted ART12.11's enhanced pharmacokinetics and its comparable efficacy to Epidiolex in rats. The results suggest that ART12.11 could significantly alleviate anxiety and depressive symptoms. Artelo is currently working on optimizing the drug's delivery formulation to maximize its therapeutic potential.
Read more →ARTLArtelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform
Artelo Biosciences presented data at the ICRS Symposium highlighting the potential therapeutic uses of its FABP5 inhibitor platform. Key findings include the efficacy of ART26.12 in combatting cancer and its promise in treating psoriasis and anxiety disorders. This includes ART26.12's comparable performance to existing treatments in psoriasis models. The company plans to initiate first-in-human trials next year, reflecting their commitment to develop effective, non-opioid solutions for various ailments.
Read more →ARTLArtelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences has presented promising preclinical data on ART26.12, a novel FABP5 inhibitor, at the ICRS Symposium. The data demonstrated ART26.12's effectiveness in alleviating pain associated with breast cancer-induced bone pain. This presentation marks the fourth in a series of studies validating the drug's efficacy. The company is optimistic about initiating human trials pending regulatory approval. ART26.12 could significantly improve treatment options for cancer-related pain, where current therapies often fall short.
Read more →ARTLArtelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
Artelo Biosciences announced the presentation of new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The data highlights the efficacy of ART26.12 as a fatty acid-binding protein 5 inhibitor, showing its potential in reducing pain caused by cancer and diabetic neuropathy. Additionally, the company plans to submit an Investigational New Drug application to the FDA for neuropathic pain treatment later this month. Overall, ART26.12 represents a pioneering approach to non-opioid pain relief, addressing significant needs in pain management.
Read more →ARTLArtelo Biosciences Presents Highly Encouraging Data Towards Developing a Solid Dosage Form of ART12.11 at CT-CANN24
Artelo Biosciences presented promising pre-clinical data on its cannabinoid formulation ART12.11 at the CT-CANN24 conference. The data demonstrates pharmacokinetics comparable to the FDA-approved Epidiolex while showing advantages in solid dosage forms for broader populations. The findings suggest ART12.11 could outperform traditional CBD formulations and may lead to reduced pill burdens for patients. Artelo is optimistic about the composition's improved characteristics and plans to develop an optimized tablet for clinical studies.
Read more →ARTLArtelo Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
Artelo Biosciences, Inc. reported its financial results for Q1 2024, indicating ongoing progress in its clinical development pipeline. The company is preparing to submit its Investigational New Drug (IND) application for ART26.12, aimed at treating neuropathic pain, and has received positive feedback from preclinical studies. Financially, Artelo holds over $7.6 million in cash and investments, although it reported a net loss of $2.5 million during the same period. The company is also advancing ART27.13 in the Cancer Appetite Recovery Study (CAReS) to address cancer-related anorexia.
Read more →ARTLArtelo Biosciences to Present at the Pharma Partnering Summit 2024 on May 14th
Artelo Biosciences, Inc. will participate in the 2024 Pharma Partnering Summit in San Diego on May 14-15, 2024. CEO Gregory D. Gorgas is set to present on May 14. This summit, known for its international focus on deal-making in life sciences, offers Artelo a platform to connect with potential partners for collaboration and growth.
Read more →ARTLArtelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Artelo Biosciences has announced the publication of a peer-reviewed article highlighting the role of fatty acid binding protein 7 (FABP7) in various cancers, indicating its potential as a novel therapeutic target. The research suggests that both genetic and pharmacological inhibition of FABP7 leads to reduced tumor growth and improved patient survival rates, particularly in brain cancer. Additionally, Artelo is advancing ART26.12, a compound aimed at treating chemotherapy-induced peripheral neuropathy, with plans to file an IND application with the FDA in Q2 2024.
Read more →ARTLArtelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will appear on the Benzinga All Access show on April 23, 2024. The live broadcast will showcase the company's focus on developing therapies for cancer, pain, and other conditions. The event underscores Artelo's commitment to engage with investors and promote its innovative therapeutics. An archived recording of the presentation will also be available on the company’s investor relations website.
Read more →ARTLArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Artelo Biosciences has reported its fiscal year-end results for 2023 and outlined significant advancements in its clinical programs. The Cancer Appetite Recovery Study (CAReS) has successfully moved from phase 1b to phase 2a, with promising data on the treatment ART27.13 for cancer anorexia. Financially, the company has $10.4 million in cash and investments and a reduced net loss compared to the previous year. Plans for IND submission of ART26.12 for neuropathic pain are progressing, bolstering the company's pipeline.
Read more →ARTLArtelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
Artelo Biosciences has been selected as a finalist in Johnson & Johnson's Innovation Challenge, presenting its research on ART26.12, a novel inhibitor targeting FABP5. This selection highlights the company's innovative approach in treating various conditions, including atopic dermatitis. The presentation occurred at the American Academy of Dermatology Annual Meeting. Positive preclinical results for ART26.12, including its effects on psoriasis models, suggest promising therapeutic potential.
Read more →ARTLArtelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
Artelo Biosciences announced the publication of new research demonstrating the effectiveness of ART26.12 in treating and preventing oxaliplatin-induced peripheral neuropathy (OIPN). The research highlights ART26.12 as a novel inhibitor of FABP5 that showed promising results in multiple preclinical studies. The company plans to file an investigational new drug (IND) application for ART26.12 in the first half of 2024, given its potential in addressing a significant demand in the neuropathic pain market.
Read more →ARTLArtelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
Artelo Biosciences has chosen Worldwide Clinical Trials as the clinical research organization to assist in the first-in-human study of ART26.12, a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy. The company aims to file an Investigational New Drug application with the FDA in the first half of the year after previously obtaining positive feedback from the agency. Artelo's preclinical studies have shown positive results, highlighting the potential of ART26.12 as a novel treatment option in the growing neuropathic pain market. The collaboration is expected to leverage Worldwide's extensive experience in advancing clinical trials.
Read more →ARTLArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Artelo Biosciences presented new preclinical data on ART12.11, its proprietary cocrystal of cannabidiol and tetramethylpyrazine, at the 4th Annual Med-Cannabis 2023 conference in Germany. The data showcased ART12.11's improved bioavailability and efficacy compared to traditional CBD, with promising anxiolytic and anti-depressive effects. This presentation reinforces the potential of ART12.11 to advance CBD therapeutic applications, backed by a patent that ensures protection until 2038.
Read more →ARTLArtelo Biosciences to Present Important New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
Artelo Biosciences is set to present new preclinical data on ART12.11, a proprietary cocrystal of cannabidiol, at the 4th Annual Med-Cannabis 2023 conference in Frankfurt, Germany. The company believes that the unique cocrystallization method grants ART12.11 significant advantages in pharmacokinetics and efficacy. These findings indicate the potential for ART12.11 to emerge as a leading treatment for anxiety and other conditions where CBD has previously shown benefits. This presentation highlights the company's commitment to advancing lipid-signaling therapeutics.
Read more →ARTLArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
Artelo Biosciences has reported its financial results for Q3 2023, highlighting a cash balance of $12.9 million which is projected to sustain operations until early 2025. The company is progressing on several fronts, including the anticipated submission of an Investigational New Drug application for ART26.12 in the first half of 2024 and completing patient enrollment in the Phase 2a Cancer Appetite Recovery Study of ART27.13. Additionally, new data on ART12.11 shows promising improved properties that could enhance therapeutic effects in chronic stress models.
Read more →ARTL▼ -8.3%on this newsshared move
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating Protective Properties of ART27.13 Against Muscle Degeneration Caused by Certain Cancers
Artelo Biosciences announced new research published in the journal Pharmaceuticals demonstrating that its drug ART27.13 can protect against muscle degeneration associated with certain cancers. The study suggests that ART27.13 may enhance the quality of life and potentially impact life expectancy for cancer patients suffering from muscle wasting. Currently, ART27.13 is being evaluated in the Cancer Appetite Recovery Study (CAReS) Phase 2a clinical trial, focusing on its efficacy to alleviate anorexia and weight loss in cancer patients. The findings support ongoing trials and indicate significant market potential for ART27.13 in oncology treatment.
Read more →ARTLArtelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
Artelo Biosciences is set to present preclinical data on two of its compounds, ART26.12 and ART12.11, at the upcoming Neuroscience 2023 conference. ART26.12 is a fatty acid binding protein inhibitor aimed at treating anxiety and depression, while ART12.11 is a proprietary cocrystal of cannabidiol that has shown enhanced effectiveness. The conference will take place from November 11 to 15, 2023, attracting a large number of researchers and clinicians. Following this, the company plans to file an Investigational New Drug application for ART26.12 in early 2024.
Read more →ARTLArtelo Biosciences to Present at the 13th Congress of the European Pain Federation on September 20th
Artelo Biosciences announced that Professor Saoirse O'Sullivan will present their findings on ART26.12 at the 13th Congress of the European Pain Federation on September 20, 2023. ART26.12 is a FABP inhibitor under development for chemotherapy-induced peripheral neuropathy, with plans to file an IND application in the first half of 2024. The conference will provide a platform to discuss the implications of this research in treating neuropathic pain, which currently lacks approved therapies.
Read more →ARTL▼ -22.6%on this news· ran to -33% by day 3
Artelo Biosciences Completes Positive Pre-IND Meeting with FDA for ART26.12
Artelo Biosciences has announced the completion of a favorable pre-IND meeting with the FDA for its drug ART26.12, aiming to treat neuropathic pain. Following FDA feedback, the company is set to file an IND application by mid-2024. ART26.12 is being developed as a first-in-class orally administered Fatty Acid Binding Protein 5 (FABP5) inhibitor, initially targeting chemotherapy-induced peripheral neuropathy. The guidance received from the FDA is viewed as validating for Artelo's development plans.
Read more →ARTL▲ +27%on this newsshared move
Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
Artelo Biosciences is set to present at the 6th Cannabinoid-Derived Drug Development Summit on September 12, 2023, with focus on improving CBD formulations. Myles Osborn, a medicinal chemist, will discuss the potential advantages of ART12.11, a proprietary CBD co-crystal, in enhancing drug properties for better absorption and efficacy. Preclinical studies suggest ART12.11 may lead to improved outcomes for patients with conditions like cancer and anxiety. The presentation is part of Artelo's ongoing efforts to address unmet medical needs through innovative cannabinoid therapies.
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
Artelo Biosciences, a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13, 2023, in New York City. CEO Gregory Gorgas is scheduled to present on September 13 at 2:00 PM ET, with the presentation available via live webcast. Additionally, management will participate in one-on-one meetings with eligible investors during the conference to foster further engagement.
Read more →ARTLArtelo Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update
Artelo Biosciences reported its second quarter 2023 financial results, highlighting the initiation of a Phase 2a trial for ART27.13 aimed at treating cancer-related anorexia. The company presented encouraging preclinical data for ART12.11 and ART26.12 at a major symposium, indicating their effectiveness in animal studies. Despite these advancements, Artelo reported a net loss of $1.6 million and a decrease in cash reserves year-over-year. Overall, the company remains optimistic about its pipeline and financial resources to meet forthcoming development milestones.
Read more →ARTLArtelo Biosciences to Present New Mechanism of Action Data on ART26.12 at the Gordon Research Conference on July 20, 2023
Artelo Biosciences is set to present new data on its lead compound, ART26.12, during the Gordon Research Conference in Spain. The research highlights the therapeutic potential of fatty acid binding protein inhibitors in treating various painful neuropathies. ART26.12 has been selected from Artelo’s library of compounds and aims to address critical areas of unmet medical need. The company anticipates receiving feedback from the FDA on its IND plans by the third quarter of this year.
Read more →ARTLArtelo Biosciences CEO to Participate in the Benzinga All Access Event on July 11
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will be participating in the Benzinga All Access event on July 11, 2023. This event serves as a platform for executives to communicate with investors and provide insights into their companies. Artelo is focused on developing therapies targeting various conditions by modulating lipid-signaling pathways. The live presentation can be viewed online, and an archived version will be available for later access.
Read more →ARTLArtelo Biosciences Announces Sponsorship of The William A. Devane Early Career Investigator Award at the 33rd Annual International Cannabinoid Research Society Symposium
Artelo Biosciences has announced its continued sponsorship of The William A. Devane Early Career Investigator Award at the 33rd International Cannabinoid Research Society Symposium in Toronto. The 2023 award recipient, Dr. Josée Guindon, will present her findings on sex differences in endocannabinoid signaling pathways related to chronic pain and cancer. Artelo also shared new preclinical research data indicating the superior efficacy of its proprietary compounds, ART12.11 and ART26.12, in treating anxiety and neuropathic pain. The company's involvement in the award supports both high-quality research and the development of professional collaborations.
Read more →ARTLArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
Artelo Biosciences announced positive preclinical data for ART26.12 at the International Cannabinoid Research Society Symposium. The novel FABP5 inhibitor demonstrated favorable effects in models of chemotherapy-induced peripheral neuropathy and diabetic neuropathy. The company anticipates a significant milestone with FDA pre-IND meeting minutes expected in the third quarter of 2023. This promising data supports the potential for ART26.12 to address the significant unmet needs in the neuropathic pain market.
Read more →ARTLArtelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
Artelo Biosciences announced promising preclinical findings for ART12.11, a cocrystal form of cannabidiol (CBD), at the 33rd International Cannabinoid Research Society Symposium. The studies highlighted ART12.11's enhanced bioavailability and efficacy in alleviating stress-induced anxiety compared to traditional CBD formulations. This innovative product aims to address significant unmet needs in the $11 billion global anxiety and depression market, potentially benefiting many patients suffering from these conditions. Artelo emphasizes ART12.11's advantages in terms of safety and pharmacokinetics, positioning it as a preferred choice among CBD therapies.
Read more →ARTL▲ +10.3%on this news
Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
Artelo Biosciences has announced that it will present positive research findings on ART12.11 at the 33rd International Cannabinoid Research Society Symposium. Scheduled for June 25, Professor Saoirse O'Sullivan will discuss data from preclinical studies focusing on stress-induced anxiety and depression. The proprietary cocrystal formulation of synthetic cannabidiol is reported to have superior pharmacokinetics compared to traditional forms of CBD, which could lead to improved outcomes for patients with mental health issues. Artelo's advancements, including four issued patents on ART12.11, position it as an innovator in the cannabinoid therapeutic space.
Read more →ARTLArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Artelo Biosciences reported its first-quarter financial results for 2023, revealing a net loss of approximately $2.2 million. The company announced progress in its Cancer Appetite Recovery Study (CAReS), moving to Phase 2a following positive safety data from the Phase 1b trial. Additionally, Artelo obtained regulatory approval to expand treatment options and participant numbers in the ongoing study, ensuring robust advancement of its drug candidate, ART27.13.
Read more →ARTL▼ -21.7%on this news· ran to -39% by day 3
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Artelo Biosciences has commenced the Phase 2a portion of its Cancer Appetite Recovery Study (CAReS) to evaluate ART27.13 for treating cancer-related anorexia and weight loss. The trial will involve 40 patients in a double-blind, placebo-controlled study conducted across various clinical sites. ART27.13 has shown favorable tolerability in earlier trials, prompting its advancement to this phase, with an expected patient enrollment completion by mid-2024. The company aims to address a significant market need for managing appetite loss in cancer patients, which is crucial for enhancing treatment outcomes.
Read more →ARTL▲ +7.9%on this news
Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
Artelo Biosciences reported its fiscal 2022 results, marking significant clinical progress in its Cannabis Appetite Recovery Study (CAReS) with ART27.13, aimed at treating cancer-related anorexia. The company is well-funded into the second half of 2024 and plans to advance its product pipeline. Positive developments include the classification of ART27.13 as 'non-controlled' in the UK, which should enhance its commercial potential. However, Artelo faced increased operating expenses and a heightened net loss compared to the previous year.
Read more →ARTLArtelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Artelo Biosciences has completed enrollment in the Phase 1b stage of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The company is encouraged by the safety profile observed in participants thus far. Further data analysis will help determine the optimal dose for the subsequent Phase 2a stage, which will further evaluate ART27.13's efficacy and safety. Artelo anticipates expanding the trial to additional sites across Europe shortly.
Read more →ARTLArtelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
Artelo Biosciences, Inc. is set to present at the Sequire Biotechnology Conference on February 2, 2023. CEO Gregory Gorgas will provide updates on the company's Cancer Appetite Recovery Study (CAReS) during the virtual event. This presentation is significant as the biotechnology sector continues to experience substantial growth, reflecting a promising environment for emerging biopharma companies. The event is expected to attract thousands of biotechnology investors, highlighting multiple public companies in the space.
Read more →ARTLArtelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Enrollment of Phase 2a CAReS Study Expected to Commence Near Year-End $19.5 Million in Cash and Investments as of September 30, 2022 SOLANA BEACH, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused
Read more →ARTLArtelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
SOLANA BEACH, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today a
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today a
Read more →ARTL▲ +45.9%on this news
Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
SOLANA BEACH, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today an
Read more →ARTL▼ -23.7%on this news
Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
CAReS Study Evaluating ART27.13 in Cancer Anorexia Progresses to Fourth Cohort ART26.12 Program to Target Chemotherapy-Induced Peripheral Neuropathy $21.3 Million in Cash and Investments as of June 30, 2022 15-for-1 Reverse Stock Split to be Effective August 10, 2022 SOLANA B
Read more →ARTLArtelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
SOLANA BEACH, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today an
Read more →ARTLArtelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain
SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announce
Read more →ARTLArtelo Biosciences Selected for Oral Presentation at the 32nd Annual ICRS Symposium in Galway, Ireland
SOLANA BEACH, Calif., June 24, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announce
Read more →ARTLArtelo Biosciences to Present at the LD Micro Invitational XII on June 7th
SOLANA BEACH, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical-stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announc
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright Global Investment Conference on May 24th
SOLANA BEACH, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. “Artelo” or the “Company”) (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced
Read more →ARTL▲ +7.7%on this newsshared move
Artelo Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
$23.5 Million in Cash and Investments as of March 31, 2022, Expected to Support Completion of the CAReS Trial and Operations Into Second Half of 2023 Results of Phase 1b CAReS Trial Anticipated in Q3 2022 SOLANA BEACH, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences
Read more →ARTL▲ +20.4%on this news
Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia
SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today a
Read more →ARTL▼ -7.3%on this news
Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer
SOLANA BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announc
Read more →ARTLArtelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced it has been invited to p
Read more →ARTL▲ +7.3%on this news· ran to +33% by day 3shared move
Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update
SOLANA BEACH, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating r
Read more →ARTL▲ +14.3%on this news
Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol
SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announc
Read more →ARTLArtelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinic
Read more →ARTLArtelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical cannabinoid, ART27.13, as “non-controlled” and, therefore, is no longer considered a Schedule
Read more →ARTL▼ -8%on this newsshared move
Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference
SOLANA BEACH, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be part
Read more →ARTL▼ -6.9%on this news
Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating re
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas
Read more →ARTLArtelo Biosciences Announces Publication of Study Results Comparing the Pharmacological Effects of Plant-Derived Versus Synthetic Cannabidiol in Human Cell Lines
Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s strategy to develop a synthetic CBD-cocrystal with enhanced pharmaceutical properties
Read more →ARTLArtelo Biosciences Reports Third Quarter Fiscal 2021 Financial Results and Provides Business Update
Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021 SOLANA BEACH, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL),
Read more →ARTLArtelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that mana
Read more →ARTLArtelo Biosciences Announces Two Poster Presentations Featured at the 31st Annual ICRS Symposium
Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11 CBD Cocrystal and the Effects of CBD and TMP Coadministration in Cancer LA JOLLA, Calif., June 22, 2021 (GLOBE NEW
Read more →ARTLArtelo Biosciences to Present at the LD Micro Virtual Invitational XI on June 9th
LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced th
Read more →ARTLArtelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update
Recently Commenced Patient Enrollment in Phase 1/2 CAReS Study of ART27.13 in the UK Reported Positive Pre-Clinical Data Associated with Artelo’s Proprietary CBD Cocrystal $11.2 Million of Cash and Cash Equivalents and Marketable Securities as of February 28, 2021 LA JOLLA, Ca
Read more →ARTLArtelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Initial safety data expected from CAReS Study before end of 2021 Targeting multi-billion market with no approved therapies for cancer-related anorexia LA JOLLA, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutica
Read more →ARTLArtelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development
Detection of elevated FABP5 associated with additional tumor types suggests the target for ART26.12 may be more broadly relevant in cancer therapy Alderley Park Oncology Development Program is a UK program designed to develop and progress innovative oncology projects LA JOLLA,
Read more →ARTLArtelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd
LA JOLLA, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that G
Read more →ARTLArtelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors
LA JOLLA, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced the appo
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th
LA JOLLA, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that Gregory Gorgas,
Read more →ARTLArtelo Biosciences Announces Positive Pre-Clinical Data Associated with Proprietary CBD Cocrystal
LA JOLLA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) today announced that Saoirse O’Sullivan, Ph.D., Professor of Pharmacology and Scientific Advisor to Artelo, along with Ryan Maguire and Dr. Timothy England of the University of Nottingham,
Read more →ARTLArtelo Biosciences Announces Appointment of Andrew Yates, Ph.D. as Senior Vice President and Chief Scientific Officer
LA JOLLA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced th
Read more →ARTLArtelo Biosciences Receives $3.0 Million in Net Proceeds from Exercise of Warrants
LA JOLLA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the exercise of a por
Read more →ARTLArtelo Biosciences Announces Research Collaboration with Trinity College Dublin to Investigate ART27.13 for the Treatment of Cancer Cachexia
LA JOLLA, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) today embarks on a collaboration with researchers from Trinity College Dublin to investigate pre-clinical models of human cancer cachexia, a wasting syndrome that affects up to 80% of all
Read more →ARTLArtelo Biosciences to Present at the LSX World Congress Virtual Conference
LA JOLLA, Calif., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it will be prese
Read more →ARTLArtelo Biosciences Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Update
Received Clinical Trial Authorization to Commence Cancer Appetite Recovery Phase I/II Clinical Study of ART27.13 in UK Awarded Mitacs Accelerate Grant LA JOLLA, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright BioConnect 2021 Conference
LA JOLLA, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright BioConnect 2
Read more →ARTLArtelo Biosciences Files Patent Application for New Formulation of ART27.13
LA JOLLA, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced th
Read more →ARTLArtelo Biosciences to Present at The 13th Annual LD Micro Main Event Conference on December 15th
LA JOLLA, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced th
Read more →ARTLArtelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors
LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced th
Read more →ARTLArtelo Biosciences and University of Western Ontario Awarded Research Grant by Mitacs
LA JOLLA, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported tha
Read more →ARTLArtelo Biosciences Announces Clinical Trial Authorization to Commence Cancer Appetite Recovery Study for the Treatment of Cancer-Related Anorexia and Weight Loss
First patients on track for enrollment this year Targeting multi-billion market with no approved therapies for cancer-related anorexia LA JOLLA, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused
Read more →ARTLArtelo Biosciences Reports Fourth Quarter and Fiscal 2020 Year-End Financial Results and Provides Business Update
Closed $7.6 Million Underwritten Public Offering Received Ethics Approval to Commence CAReS Study of ART27.13 in the UK Expanded Exclusive Worldwide License with Stony Brook University for Fatty Acid Binding Protein 5 (FABP5) inhibitor Platform LA JOLLA, Calif., Nov. 04, 2020
Read more →ARTLArtelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological Disorders
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, t
Read more →ARTLArtelo Biosciences, Inc. Announces Closing of $7.6 Million Underwritten Public Offering and Full Exercise of Underwriters’ Option
LA JOLLA, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, t
Read more →ARTLArtelo Biosciences, Inc. Announces Pricing of $6.6 Million Upsized Underwritten Public Offering
LA JOLLA, Calif., Oct. 09, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, t
Read more →ARTLArtelo Biosciences Receives Ethics Approval to Commence its Cancer Appetite Recovery Phase I/II Clinical Study (CAReS) of ART27.13 for the Treatment of Cancer-Related Anorexia
LA JOLLA, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the receipt of Ethics Committee approval i
Read more →ARTLArtelo Biosciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15th
LA JOLLA, Calif., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the H.C. Wainwright Annual Glob
Read more →ARTLArtelo Biosciences to Participate in Two Keynote Panels at 3rd Annual International Cannabinoid Derived Pharmaceutical Summit
LA JOLLA, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer and Andy Yate
Read more →ARTLArtelo Biosciences Reports Third Quarter Fiscal Year 2020 Financial Results and Provides Business Update
LA JOLLA, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling pathways, today reported fi
Read more →ARTLArtelo Biosciences Expands Stony Brook Commercial License Agreement for FABP5 Platform for Development of Lead Cancer, Pain and Inflammation Compounds
LA JOLLA, Calif., June 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded its existing research
Read more →ARTLArtelo Biosciences to Participate in BIO Digital and The Investor Summit Conferences
LA JOLLA, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system and related pathways, announced today that it will be participating in two upco
Read more →ARTLArtelo Biosciences Awarded Composition of Matter Patent for Novel CBD Cocrystal
LA JOLLA, Calif., May 12, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on developing proprietary therapeutics that target the endocannabinoid system and related biological signaling pathways, today announced
Read more →ARTLArtelo Biosciences Reports Second Quarter Fiscal Year 2020 Financial Results and Provides Business Update
LA JOLLA, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system and related biological signaling pathways, today reported f
Read more →ARTLArtelo Biosciences to Present at Biocom’s 10th Annual Global Life Sciences Partnering Conference
LA JOLLA, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that Gregory D. Gorgas, President and Chief Executive Officer
Read more →ARTLArtelo Biosciences Announces NCI Grant of $4.2 Million to Stony Brook University to Advance FABP5 Inhibitor Cancer Program
FABP5 platform under exclusive license to Artelo Biosciences NCI support provides further validation of next-generation target for cancer therapeutics LA JOLLA, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical
Read more →ARTLArtelo Biosciences to Present at the LSX World Congress in London
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the LSX World Congress to be hel
Read more →ARTLArtelo Biosciences Reports First Quarter Fiscal Year 2020 Financial Results and Provides Business Update
LA JOLLA, Calif., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the firs
Read more →ARTLArtelo Biosciences Announces Appointment of Seasoned Finance and Industry Executive John W. Beck to Board of Directors
LA JOLLA, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced the appointment of seasoned industry execut
Read more →ARTLArtelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update
LA JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and operating results for the four
Read more →ARTLArtelo Biosciences Announces Publication of Positive Non-Clinical Fatty Acid Binding Protein 5 Inhibitor Data in Peer-Reviewed Journal
LA JOLLA, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that positive non-clinical data with the Company’s Fatty Acid
Read more →ARTLArtelo Biosciences to Present at the Annual Investival Showcase in London
LA JOLLA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the Annual Investival Showcase t
Read more →ARTLArtelo Biosciences Announces Selection of Aptus Clinical Ltd. as Clinical Research Organization for Phase 1b/2a Study of ART27.13
LA JOLLA, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that it has selected Aptus Clinical Ltd. (Aptus), a specialist
Read more →ARTLArtelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
LA JOLLA, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the Dawson James Securities 5th
Read more →ARTLArtelo Biosciences Cannabidiol (CBD) Studies Referenced in September Issue of Nature Medicine
LA JOLLA, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, announced today that two research studies conducted by the Company were featu
Read more →ARTLArtelo Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
LA JOLLA, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial results for the third quarter endi
Read more →ARTLArtelo Biosciences Announces Closing of $8.0 Million Public Offering and Partial Exercise and Closing of Over-Allotment Option
LA JOLLA, Calif., June 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system, today an
Read more →ARTLArtelo Biosciences Announces Pricing of $8.0 Million Public Offering and Uplisting to Nasdaq
LA JOLLA, Calif., June 21, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NasdaqCM: ARTL, ARTLW) (the “Company” or “Artelo Biosciences”), a clinical-stage biopharmaceutical company with a portfolio of novel therapeutic candidates targeting the endocannabinoid system, today an
Read more →ARTLNEW PRECLINICAL CELL-LINE DATA OF ARTELO BIOSCIENCES' ART27.13 DEMONSTRATE ANTI-PROLIFERATIVE ACTIVITY IN TUMOR MODELS Artelo Biosciences to Be Featured On Cannabinoid Panel Discussion at LSX World Congress USA on Octobe
NEW PRECLINICAL CELL-LINE DATA OF ARTELO BIOSCIENCES' ART27.13 DEMONSTRATE ANTI-PROLIFERATIVE ACTIVITY IN TUMOR MODELS Artelo Biosciences to Be Featured On Cannabinoid Panel Discussion at LSX World Congress USA on October 11th, 2018 LA JOLLA, CA, October 9, 2018 - Artelo Biosci
Read more →Competitive Position
How ARTL ranks across every disease it competes inCompetitive Position is a premium feature
See how ARTL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial